What a terrible barrel to be looking into the end of"WORST CASE...

First 72 Last

Share
Profile

Follow
WhippedCream

481 Posts.

210

21/01/20

07:06

Post #: 42484201
Share

Originally posted by WhippedCream: ↑

Not over my head at all, I guess I just don't see the issue with the escrow shares for the following reasons.

- We are currently in suspension and not even trading
- We haven't received an annual report as yet
- We would most likely receive an annual report once debt restructuring and CR takes place
- My previous point will have to come with a prospectus, which will take a few weeks with SPP etc, so ample time is given for management to give the 10days notice.

"Chicken and the egg"

You are making claims to not presenting the egg when you don't even have a chicken yet??

I don't believe you were required to repost the same information a few posts apart, anyone with any smarts will see this as a little bit of a non issue with where Vector stands at the moment. First things first lets get a plan in place to get to market and buy that chicken.

I am just glad you painted the full picture here for once, I say you get a copy and reread it and then repost the relevance it has to a stock which is not trading and currently in voluntary suspension.

Its quite simple the shares will move into the restricted category until a annual report is supplied and notice is given 10 days prior to trading.

Not rocket science pal

Expand

What a terrible barrel to be looking into the end of

"WORST CASE THE ESCROWED SHARES REMAIN IN VOLUNTARY ESCROW UNTIL NOTICE IS GIVEN"

OH MY GAUD THE ROOF IS DEFINITELY CAVING IN.........ERRRR UMMMM DEEHH SAID NOBODY EVER

VEC Price at posting: 1.2¢ Sentiment: None Disclosure: Not Held
3 Upvote

1 Great analysis

Reply

Top Stories

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger